Low Level of TERC Gene Amplification between Chronic Myeloid Leukaemia Patients Resistant and Respond to Imatinib Mesylate Treatment |
Mohamad Ashari, Zaidatul Shakila
(Human Genome Center, School of Medical Sciences, Health Campus, Universiti Sains Malaysia)
Sulong, Sarina (Human Genome Center, School of Medical Sciences, Health Campus, Universiti Sains Malaysia) Hassan, Rosline (Department of Haematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia) Husin, Azlan (Haemato-Oncology Unit, Department of Internal Medicine, School of Medical Sciences, Health Campus, Universiti Sains Malaysia) Sim, Goh Ai (Hospital Pulau Pinang) Wahid, S. Fadilah Abdul (Department of Medicine & Cell Therapy Center, Universiti Kebangsaan Malaysia Medical Center) |
1 | Reichard KK, Hall BK, Corn A, et al (2006). Automated analysis of fluorescence in situ hybridization on fixed, paraffinembedded whole tissue sections in B-cell lymphoma. Modern Pathology, 19, 1027-33. DOI |
2 | Ozer O, Balci TB, Yilmaz Z, et al (2011). Fluorescence in situ hybridization analysis of the hTERC region in acute myeloid leukemia patients. Turkish J Hematology, 28, 103-6. DOI |
3 | Podlevsky JD, Bley CJ, Omana RV, et al (2008). The telomerase database. Nucleic Acids Res, 36, 339-43. |
4 | Quintas-Cardama A, Kantarjian HM, Cortes JE (2009). Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control, 16, 122-31. DOI |
5 | Serakinci N, Koch JE (2002). Telomerase activity in human leukemic cells with or without monosomy 7 or 7q. BMC Medical Genetics, 3, 11. |
6 | Shay JW, Bacchetti S (1997). A survey of telomerase activity in human cancer. Eur J Cancer, 33, 787-91. DOI ScienceOn |
7 | Soder AI, Hoare SF, Muir S, et al (1997). Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene, 14, 1013- 21. DOI |
8 | Wright WE, Piatyszek MA, Rainey WE, et al (1996). Telomerase activity in human germline and embryonic tissues and cells. Dev Genet, 18, 173-9. DOI |
9 | Yamada O, Kawauchi K, Akiyama M, et al (2008). Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leukemia Lymphoma, 49, 1168-77. DOI ScienceOn |
10 | Kokalj-Voka AN, Kodri AT, Erjavec-Kerget A, et al (2009). Screening of TERC gene amplification as an additional genetic diagnostic test in detection of cervical preneoplastic lesions. Cancer Genetics Cytogenetics, 195, 19-22. DOI ScienceOn |
11 | Gurkan E, Tanriverdi K, Baslamisli F (2005). Telomerase activity in myelodysplastic syndromes. Leukemia Res, 29, 1131-9. DOI ScienceOn |
12 | Heselmeyer-Haddad K, Sommerfeld K, White NM, et al (2005). Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol, 166, 1229-38. DOI ScienceOn |
13 | Kim NW, Piatyszek MA, Prowse KR, et al (1994). Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011-15. DOI ScienceOn |
14 | Kyo S, Takakura M, Fujiwara T, Inoue M (2008). Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci, 99, 1528-38. DOI ScienceOn |
15 | Masutomi K, Yu EY, Khurts S, et al (2003). Telomerase maintains telomere structure in normal human cells. Cell, 114, 241-53. DOI ScienceOn |
16 | Mitelman F, Johansson B, Mertens F (2004). Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genetics, 36, 331-4. DOI ScienceOn |
17 | Nowak T, Januszkiewicz D, Zawada M, et al (2006). Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase. Oncol Rep, 16, 301-5. |
18 | Ohyashiki JH, Sashida G, Tauchi T, et al (2002). Telomeres and telomerase in hematologic neoplasia. Oncogene, 21, 680-7. DOI ScienceOn |
19 | Cong YS, Wright WE, Shay JW (2002). Human telomerase and its regulation. Microbiol Mol Biol Rev, 66, 407-25. DOI ScienceOn |
20 | Cao Y, Bryan TM, Reddel RR (2008). Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci, 99, 1092-99. DOI ScienceOn |
21 | Chen M, Xing L-N (2012) siRNA-mediated inhibition of hTERC enhances radiosensitivity of cervical cancer. Asian Pac J Cancer Prev, 13, 5975-9. DOI ScienceOn |
22 | Chen Q, Wang X, Ru Y, et al (2011) Amplification of the telomerase RNA component gene in the process of human esophageal carcinogenesis. Tohoku J Exp Med, 224, 99-104. DOI ScienceOn |
23 | Cortes J, Hochhaus A, Hughes T, et al (2011). Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol, 29, 524-31. DOI ScienceOn |
24 | Gabert J, Beillard E, Van der Velden V, et al (2003). Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia, 17, 2318-57. DOI ScienceOn |
25 | Goldman JM (2008). Chronic myeloid leukaemia. Medicine, 37, 195-7. |
26 | Gozzetti A, Le Beau MM (2000). Fluorescence in situ hybridization: uses and limitations. Semin Hematol, 37, 320-33. DOI ScienceOn |
27 | Graf SW, Lester S, Nossent JC, et al (2012). Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. Arthritis Res Ther, 14, 28. |
28 | Gugliotta G, Castagnetti F, Palandri F, et al (2011). Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CMLWorking Party. Blood, 117, 5591-99. DOI ScienceOn |
29 | Albertson DG, Collins C, McCormick F, et al (2003). Chromosome aberrations in solid tumours. Nature Genetics, 34, 369-76. DOI ScienceOn |
30 | Andersson S, Wallin KL, Hellstro AC, et al (2006). Frequent gain of human telomerase gene TERC at 3q26 in Cervical Adenocarcinomas. Br J Cancer, 95, 331-8. DOI ScienceOn |
31 | Bakalova R, Ohba H, Zhelev Z, et al (2003). Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Pharmacol, 66, 1879-84. DOI ScienceOn |
32 | Bignold LP (2006) Cancer: Cell Structures, Carcinogens and Genomic Instability, Springer, 1-19. |
33 | Breccia M, Efficace F, Alimena G (2010). Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? Cancer Lett, 300, 115-21. |
34 | Liu Y, Dong XL, Tian C, et al (2012). Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagnostic Pathol, 7, 34. DOI ScienceOn |
![]() |